BioCentury | Feb 16, 2015
Clinical News

Pheburane sodium phenylbutyrate regulatory update

...4-phenylbutyrate is approved as adjunctive therapy for the chronic management of UCD in the EU. Lucane Pharma S.A....
BioCentury | Oct 6, 2014
Clinical News

Pheburane regulatory update

...it has Orphan Drug status. The product also has Orphan Drug designation in the U.S. Lucane Pharma S.A....
BioCentury | Dec 21, 2013
Company News

CHMP backs J&J TB compound, Piramal imaging agent

...Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Para-aminosalicylic acid Lucane from Lucane Pharma S.A....
BioCentury | Dec 16, 2013
Company News

Le Groupe Pharmaceutique Boivin, Lucane Pharma sales and marketing update

...financial terms, and Lucane could not be reached. Le Groupe Pharmaceutique Boivin , Montreal, Quebec Lucane Pharma S.A....
BioCentury | Nov 25, 2013
Clinical News

PAS-GR regulatory update

...designation in the EU for tuberculosis, is already available in France under a compassionate-use program. Lucane Pharma S.A....
BioCentury | Nov 23, 2013
Company News

CHMP backs TB compounds from Otsuka, Lucane

...Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Para-aminosalicylic acid Lucane from Lucane Pharma S.A....
BioCentury | Mar 4, 2013
Clinical News

Pheburane regulatory update

...EMA's CHMP recommended approval of an MAA from Lucane Pharma for pheburane for adjunctive therapy in the...
...urea cycle disorders. The formulation of sodium 4-phenylbutyrate has Orphan Drug designation in the EU. Lucane Pharma S.A....
BioCentury | Aug 20, 2012
Clinical News

PAS-GR regulatory update

...to treat tuberculosis. PAS-GR is para-aminosalicylic acid. The company could not be reached for details. Lucane Pharma S.A....
Items per page:
1 - 8 of 8
BioCentury | Feb 16, 2015
Clinical News

Pheburane sodium phenylbutyrate regulatory update

...4-phenylbutyrate is approved as adjunctive therapy for the chronic management of UCD in the EU. Lucane Pharma S.A....
BioCentury | Oct 6, 2014
Clinical News

Pheburane regulatory update

...it has Orphan Drug status. The product also has Orphan Drug designation in the U.S. Lucane Pharma S.A....
BioCentury | Dec 21, 2013
Company News

CHMP backs J&J TB compound, Piramal imaging agent

...Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Para-aminosalicylic acid Lucane from Lucane Pharma S.A....
BioCentury | Dec 16, 2013
Company News

Le Groupe Pharmaceutique Boivin, Lucane Pharma sales and marketing update

...financial terms, and Lucane could not be reached. Le Groupe Pharmaceutique Boivin , Montreal, Quebec Lucane Pharma S.A....
BioCentury | Nov 25, 2013
Clinical News

PAS-GR regulatory update

...designation in the EU for tuberculosis, is already available in France under a compassionate-use program. Lucane Pharma S.A....
BioCentury | Nov 23, 2013
Company News

CHMP backs TB compounds from Otsuka, Lucane

...Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Para-aminosalicylic acid Lucane from Lucane Pharma S.A....
BioCentury | Mar 4, 2013
Clinical News

Pheburane regulatory update

...EMA's CHMP recommended approval of an MAA from Lucane Pharma for pheburane for adjunctive therapy in the...
...urea cycle disorders. The formulation of sodium 4-phenylbutyrate has Orphan Drug designation in the EU. Lucane Pharma S.A....
BioCentury | Aug 20, 2012
Clinical News

PAS-GR regulatory update

...to treat tuberculosis. PAS-GR is para-aminosalicylic acid. The company could not be reached for details. Lucane Pharma S.A....
Items per page:
1 - 8 of 8